Reviewing Innocoll (INNL) & Impax Laboratories (IPXL)
Innocoll (NASDAQ: INNL) and Impax Laboratories (NASDAQ:IPXL) are both small-cap pharmaceuticals – nec companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.
Valuation & Earnings
This table compares Innocoll and Impax Laboratories’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Impax Laboratories||$824.43 million||1.81||-$472.03 million||($6.25)||-3.22|
This table compares Innocoll and Impax Laboratories’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings and target prices for Innocoll and Impax Laboratories, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Innocoll presently has a consensus price target of $3.00, indicating a potential upside of 27.66%. Impax Laboratories has a consensus price target of $20.29, indicating a potential upside of 0.67%. Given Innocoll’s higher probable upside, research analysts plainly believe Innocoll is more favorable than Impax Laboratories.
Institutional & Insider Ownership
34.2% of Innocoll shares are owned by institutional investors. Comparatively, 90.5% of Impax Laboratories shares are owned by institutional investors. 3.2% of Impax Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Impax Laboratories beats Innocoll on 8 of the 11 factors compared between the two stocks.
Innocoll Company Profile
Innocoll Holdings Public Limited Company is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically. Using its processes at its manufacturing facility, it derives and purifies bovine and equine collagen and then utilizes its technology platform to incorporate the purified collagen into its topical and implantable products. Its lead product candidates are XaraColl for the treatment of post-operative pain and Cogenzia for the treatment of diabetic foot infections. Its marketed products include CollaGUARD, Collatamp, Septocoll and RegenePro. It has initiated its Phase III efficacy trials for Cogenzia.
Impax Laboratories Company Profile
Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.
Receive News & Ratings for Innocoll Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innocoll and related companies with MarketBeat.com's FREE daily email newsletter.